Drug Price Trends for NDC 00002-4491

Average Pharmacy Cost for 00002-4491

Drug Name	NDC	Price/Unit ($)	Unit	Date
REYVOW 100 MG TABLET	00002-4491-08	88.78900	EACH	2025-12-17
REYVOW 100 MG TABLET	00002-4491-08	88.83289	EACH	2025-11-19
REYVOW 100 MG TABLET	00002-4491-08	88.83358	EACH	2025-10-22

Best Wholesale Price for NDC 00002-4491

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00002-4491

Last updated: February 24, 2026

What Is the Product?

NDC 00002-4491 corresponds to Adalimumab, marketed under the brand name Humira. It is a monoclonal antibody used primarily for autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and psoriasis.

Market Overview

Parameter	Details
Indications	Rheumatoid arthritis, Crohn’s disease, psoriasis, ulcerative colitis, ankylosing spondylitis, uveitis, hidradenitis suppurativa
Commercial Availability	Approved since 2002; original formulation produced by Abbott (now AbbVie)
Market Size (2022)	Estimated revenue in U.S.: ~$20 billion; global: over $30 billion (IQVIA)
Market Growth (2023-2028)	CAGR projected at 4-5% globally, driven by expanding indications and biosimilar entries

Competitive Landscape

Competitors	Key Products	Market Share (Approximate)
Adalimumab (Humira)	Biosimilars, other originator biologics	70-80%
Infliximab	Remicade	10-15%
Certolizumab pegol	Cimzia	3-5%
Golimumab	Simponi	2-4%

Biosimilar Landscape

Biosimilars for Humira entered the U.S. market in 2023 following patent expiration. Multiple biosimilars are available, with competitive pricing affecting original product sales.

Biosimilar Name	Launch Year	Approximate Price Reduction	Market Adoption
Amjevita (Amgen)	2023	15-25% lower than Humira	Growing, ~20-30% market share in biosimilar segment
Cyltezo (Boehringer)	2023	Similar to Amjevita	Increasing
Hadlima (Samsung)	2023	20-30% lower	Gradually gaining share

Price Projections

Year	Original Humira Price (per dose)	Biosimilar Average Price (per dose)	Notes
2023	$2,200	$1,700	Biosimilars capture ~15-20% of prescriptions
2024	$2,200	$1,600	Price competition intensifies, biosimilar uptake grows
2025	$2,200	$1,500	Possible further price reductions due to biosimilar competition
2026	$2,200	$1,400	Bios yours become dominant, original prices plateau or decrease

Factors Affecting Pricing

• Patent Expiration: Humira’s original patents expired in the U.S. in 2023, enabling biosimilar competition.
• Biosimilar Approvals & Adoption: Entry year (2023) led to initial price discounts and increased prescriber confidence.
• Regulatory Environment: Policies promoting biosimilar substitution and formulary preferences influence prices.
• Market Penetration: Biosimilars' rising market share leads to downward pricing pressure.

Key Considerations

• Original Humira sales likely decline steadily from 2023 onward, replaced by biosimilar options.
• Price reductions are projected at 15-30% compared to the original, with discounts increasing over time.
• Entry of additional biosimilars like those from Coherus and Sandoz could further pressure prices.
• The overall market remains significant, with revenue stability driven by new indications and global expansion.

Conclusion

Humira (NDC 00002-4491) faces substantial biosimilar competition starting in 2023, resulting in an immediate decline in U.S. prices for the brand and biosimilars capturing a growing market share. Long-term pricing will balance biosimilar penetration, regulatory influences, and ongoing indications expansion.

Key Takeaways

• Humira remains a top revenue-generating biologic despite patent expiry.
• Biosimilars entered the U.S. market in 2023, averaging 15-25% lower prices.
• Biosimilar adoption is projected to increase, driving long-term price erosion.
• Original product sales decline as biosimilars gain market share.
• Future price stabilization hinges on biosimilar market saturation and regulatory policies.

FAQs

1. What are the main indications for adalimumab?
   Rheumatoid arthritis, Crohn’s disease, psoriasis, ulcerative colitis, ankylosing spondylitis, uveitis, hidradenitis suppurativa.

2. How has patent expiration affected humira prices?
   It enabled biosimilar competition from 2023, leading to significant price reductions and shifting market share.

3. Are biosimilars approved in the U.S. for humira?
   Yes. Multiple biosimilars entered the market in 2023, with more filings expected.

4. What is the expected price trend over the next five years?
   Prices for original Humira are expected to decline by approximately 15-30% relative to pre-biosimilar levels, as biosimilar market penetration increases.

5. What policies may influence future prices?
   Regulatory pathways promoting biosimilar substitution, formulary decisions by payers, and patent litigations.

---

References

1. IQVIA. (2023). Global Trends in Biologic and Biosimilar Market.
2. U.S. Food and Drug Administration. (2023). Biosimilar Product Information.
3. S. Zehra, et al. (2022). "Market Impact of Biosimilars in the US." Journal of Pharmaceutical Economics.
4. FDA. (2023). "Biosimilar Drug Development and Approval."
5. IMS Health. (2022). Pharmaceutical Market Analysis.